



Contact:

Karen A. Donato, Ph.D.
Executive Vice President, Sales and Marketing
MaxCyte, Inc.
(301) 944-1700

For Immediate Release

**MaxCyte STXpert Users Explain How to Fast Track Cell Based Assay
Development at the SBS Annual Meeting in Phoenix, Booth 342**

*MaxCyte® STX™ Scalable Transfection System for Cell Based Assays:
Data to be Presented at the 16th Annual SBS Meeting in Phoenix, AZ*

Gaithersburg, MD, April 13, 2010 –MaxCyte, Inc., the pioneer in scalable, high performance cell loading systems, will feature the MaxCyte® STX™ Scalable Transfection System at Booth 342 at the Society for Biomolecular Sciences (SBS) 16th Annual Conference & Exhibition in Phoenix, AZ, April 11-15.

Expert users of the MaxCyte STX will be available at scheduled times in Booth 342 to describe their experiences using the MaxCyte STX to accelerate the development and conduct of cell based assays for ion channel and GPCR screening. Dr. Omar Aziz of BioFocus, a leading provider of gene-to-candidate drug discovery services, will be in MaxCyte's Booth 342 on Tuesday, April 13, from 3:00-4:00 PM and available at BioFocus' booth 835 to share BioFocus' results in using the MaxCyte STX as an enabling technology for high seal and cell membrane integrity in electrophysiology assays. Dr. Steve Smith of ChanTest Corporation, a leader in integrated ion channel and GPCR services and reagents, will be in MaxCyte's Booth 342 on Wednesday, April 14, from 3:00-4:00 PM and available at ChanTest's booth 322 to describe ChanTest's experience in using the MaxCyte STX for multi-plasmid ion channel loading. Dr. James Brady, Director of Technical Applications at MaxCyte, will be available throughout the SBS Meeting to answer technical questions and to demonstrate the operation of the MaxCyte STX.

In the Advances in Assay Technology Session in Exhibit Halls 4-5 on Wednesday, April 14 from 12:00-2:30 PM, MaxCyte will present Poster B280, entitled "Creating Cell-Based Assays for Screening GPCRs, Ion Channels and Other Targets in Cell Lines and Primary Cells Using the MaxCyte® STX™ Scalable Transient Transfection System." In-house and customer generated data using the MaxCyte STX for cell based assay development will be disclosed.

Douglas Doerfler, President and CEO of MaxCyte, states: "We are delighted to have such leaders in the field as BioFocus and ChanTest using the MaxCyte STX for the development of cell based assays for ion channels and other targets as part of their service offerings. We appreciate their participation with us at the SBS Meeting to demonstrate how the MaxCyte STX can fast track the design, development, and conduct of cell-based assays, accelerating the screening of compound libraries and improving the likelihood of finding successful drug candidates."

About MaxCyte

MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell therapy

expertise, MaxCyte designed the MaxCyte® STX™ Scalable Transfection System for the rapid development and consistent production of (co)transfected primary cells, stem cells, and cell lines for cell-based screening assays for ion channels, GPCRs, and other targets, with comparable results and Seamless Scalability™ from the bench to HTS scale.

For more information, <http://www.maxcyte.com/cell-based-screening.shtml>.

###